HIV-associated neurocognitive disorders: A historical review

Neurologist

Volumn 18, Issue 2, 2012, Pages 64-67

  Cecilia, Rosca Elena ^a   Ovidiu, Rosca ^a   Mihaela, Simu ^a   Dana, Chirileanu Ruxanda ^a  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

cognition; dementia; HIV

Indexed keywords

ABACAVIR; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; INDINAVIR; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; PLACEBO; RALTEGRAVIR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; VIRUS ANTIBODY; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BRAIN DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T LYMPHOTROPIC VIRUS 3; KAPOSI SARCOMA; KNOWLEDGE; LIFE EXPECTANCY; NEUROLOGIST; NONHUMAN; PNEUMOCYSTIS CARINII; PRIORITY JOURNAL; REVIEW;

AIDS DEMENTIA COMPLEX; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COGNITION DISORDERS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HIV; HUMANS;

EID: 84858119056     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e318247bc7a     Document Type: Review

References (36)

1. Centres for Disease Control (CDC). Update on acquired immune deficiency syndrome (AIDS)-United States. MMWR Morb Mortal Wkly Rep. 1982;31:507-508, 513-514.
2. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a Tlymphotrophic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983;220:868-871. (Pubitemid 13080157)
3. Popovic M, Sarngadharan MG, Read E, et al. Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science. 1984;224: 497-500. (Pubitemid 14134740)
4. Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk of AIDS. Science. 1984;224:500-503. (Pubitemid 14134741)
5. Schupbach J, Popovic M, Gilden RV, et al. Serological analysis of a subgroup of human T-lymphotropic retroviruses (HTLV-III) associated with AIDS. Science. 1984;224:503-505. (Pubitemid 14134742)
6. Sarngadharan MG, Popovic M, Bruch L, et al. Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science. 1984;224:506-508. (Pubitemid 14134743)
7. Snider WD, Simpson DM, Nielsen S, et al. Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol. 1983;14:403-418. (Pubitemid 13010040)
8. Navia BA, Price RW. The acquired immunodeficiency syndrome dementia complex as the presenting or sole manifestation of human immunodeficiency virus infection. Arch Neurol. 1987;44: 65-69. (Pubitemid 17087614)
9. Levy RM, Bredesen DE. Central nervous system dysfunction in acquired immunodeficiency syndrome. J Acquir Immune Defic Syndr. 1988;1:41-64. (Pubitemid 19128451)
10. Janssen RS, Cornblath DR, Epstein LG, et al. Nomenclature and research case definitions for neurological manifestations of human immunodeficiency virus type-1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology. 1991;41:778-785.
11. Marder K, Albert SM, Dooneief G, et al. Clinical confirmation of the American Academy of Neurology algorithm for HIV-1 associated cognitive/motor disorder. Neurology. 1996;47:1247-1253. (Pubitemid 26374895)
12. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69: 1789-1799. (Pubitemid 350059308)
13. Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis. 1988;158:1079-1083. (Pubitemid 18266060)
14. Marder K, Albert SM, McDermott MP, et al. Inter-rater reliability of a clinical staging of HIV-associated cognitive impairment. Neurology. 2003;60:1467-1473. (Pubitemid 36554808)
15. Power C, Selnes OA, Grim JA, et al. The HIV dementia scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8:273-278.
16. Schifitto G, Kieburtz K, McDermott MP, et al. Clinical trials in HIV-associated cognitive impairment: cognitive and functional outcomes. Neurology. 2001;56:415-418. (Pubitemid 32144162)
17. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987;317:185-191. (Pubitemid 17114872)
18. Yarchoan R, Berg G, Brouwers P, et al. Response of human- immunodeficiency-virus-associated neurological disease to 3′-azido- 3′-deoxythymidine. Lancet. 1987;1:132-135. (Pubitemid 17015824)
19. Schmidt FA, Bigley JW, McKinnis R, et al. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med. 1988;319: 1573-1578. (Pubitemid 19003423)
20. Lambert JS, Seidlin M, Reichman RC, et al. 2′,3′- dideoxynosine (ddI) in patients with acquired immunodefficiency sindrome or AIDS-related complex. A phase I trial. N Engl J Med. 1990; 322:1333-1340. (Pubitemid 20154475)
21. Yarchoan R, Pluda JM, Perno CF, et al. Initial clinical experience with dideoxynucleosides as single agents and in combination therapy. Ann N Y Acad Sci. 1990;616:328-343.
22. Folkers G. Two new protease inhibitors approved by FDA. Food and Drug Administration. NIAID AIDS Agenda. 1996;4-5. (PMID:11363799).
23. Ferrando S, van Gorp W, McElhiney M, et al. Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function. AIDS. 1998;12:F65-F70. (Pubitemid 28241393)
24. Price RW, Yiannoutsos CT, Clifford DB, et al. Neurological outcomes in late HIV infection: adverse impact on neurological impairment on survival and protective effect of antiretroviral therapy. AIDS. 1999;13:1677-1685. (Pubitemid 30015715)
25. Tozzi V, Balestra P, Libertone R, et al. Cognitive function in treated HIV patients. Neurobehavioral HIV Med. 2010;2:95-113.
26. Carpenter CCJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society - USA panel. JAMA. 2000;283:381-390. (Pubitemid 30051757)
27. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008; 65:65-70.
28. Letendre S, FitzSimons C, Ellis R, et al. Correlates of CSF viral loads in 1221 volunteers of the CHARTER Cohort. Abstract 172, 17th CROI 2010.
29. European AIDS clinical society guidelines. Version 6. October 2011. Available at: http://www.europeanaidsclinicalsociety.org/index.php?option = com-content&view = article&id = 59&Itemid = 41. Accessed November 14, 2011.
30. Sacktor N, Schifitto G, McDermott MP, et al. Transdermal selegiline in HIV-associated cognitive impairment: a pilot, placebo-controlled study. Neurology. 2000;54:233-235. (Pubitemid 30038769)
31. Schifitto G, Yiannoustos CT, Ernst T, et al. Selegiline and oxidative stress in HIV-associated cognitive impairment. Neurology. 2009;73:1975-1981.
32. Rabkin JG, McElhiney MC, Rabkin R, et al. Modafinil treatment for fatigue in HIV+ patients: a pilot study. J Clin Psychiatry. 2004;65:1688-1695.
33. Schifitto G, Navia BA, Yannoutsos CT, et al. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS. 2007;21:1877-1886. (Pubitemid 47329764)
34. Zink MC, Uhrlaub J, De Witt J, et al. Neuroprotective and antihuman immunodeficiency virus activity of Minocycline. JAMA. 2005;293:2003-2011. (Pubitemid 40570894)
35. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010;24:1243-1250.
36. Hardy DJ, Vance DE. The neuropsychology of HIV/AIDS in older adults. Neuropsychol Rev. 2009;19:263-272.